We wait with bated breath for news of the recent IDMC meeting results. News could come any day now. We believe the IDMC will have ~95% of the available data for their analysis. This is enough to determine the next steps.
Three possible announcements:
You read that right. Interim analysis is done to DETERMINE FUTILITY. Tested and tested again!
It would have been deemed futile if Multikine wasn't extending survival over standard care by 10% or more!
Guess, what? As recent as March 29, 2019 the IDMC determined the LARGEST Head and Neck Trial wasn't Futile after all these years.
The IDMC's job is to check the study to assess safety, sample size and futility. This is laid out on the CT Site.
From the CT Site it says:
Primary Outcome Measures
1. Overall Survival (OS) in LI + CIZ + SOC vs. SOC
OS will be assessed using Kaplan-Meier life-table and compared using a logrank test and confirmed further with tumor stage location and geographic stratified log rank tests. The unstratified logrank test constitutes the primary analysis. A two-sided p-value of 0.05 or less will be considered statistically significant for comparing the two groups. Interim analyses will be performed throughout the study to assess safety, sample size and futility.
Last March, the IDMC reviewed the trial for Safety, sample size (ie drop outs) and Futility. ALL PASSED! It was safe, enrolled enough and with 95% of the data, hadn't been determined to be futile.
This September, with 99% of all the data in...they will do the same.
They SHUT 'EM DOWN all the time.
On April 12, 2019 The IDMC shut down TWO TRIALS!!!
Tracon Pharmaceuticals trial
"Tracon Pharmaceuticals Inc. shares TCON, -49.24% slid 45% in premarket trade Friday, after the company said it is terminating a late-stage trial of a cancer treatment at the recommendation of an independent committee. The company said its phase 3 trial evaluating TRC105 in combination with Votrient in patients with advanced or metastatic angiosarcoma, a rare kind of cancer, was terminated for futility based on the recommendation of the Independent Data Monitoring Committee following a review of data from more than 120 patients. "
"Clovis Oncology Inc said on Friday it was halting a mid-stage trial testing its lead drug in bladder cancer patients, sending shares down 12 percent.
The company said its decision to discontinue the trial was based on recommendations of an independent committee, which suggested that the treatment may not provide a meaningful benefit to patients."
On March 22, 2019 The IDMC shut down BIOGEN's Alzheimer's Study
"Biogen BIIB and its Japan-based partner Eisai announced the discontinuation of two late-stage studies evaluating their Alzheimer’s disease candidate, aducanumab. The decision was taken following a futility analysis conducted by an independent data monitoring committee (“IDMC”). The analysis showed that the studies are unlikely to meet their primary endpoints."
Stock Vadar on The IDMC from 4/7/19
Copyright © 2019 Killcvmshorts - All Rights Reserved. NOT AFFILIATED WITH CEL-SCI IN ANY CAPACITY! THIS WEBSITE SHOULD NOT BE CONSIDERED INVESTMENT ADVICE. WEBSITE CREATED BY A NUT JOB WITH TOO MUCH TIME ON HIS HANDS. THIS NUT JOB HAS SHARES OF CVM AND IS LONG. THIS NUT JOB ISNT BEING COMPENSATED FOR THIS SITE. THIS NUT JOB NEVER HAS BEEN COMPENSATED FOR ANY OF MY DUE DILIGENCE OR WORK RELATED TO CVM. ALL THESE OPINIONS ARE OF A NUT JOB.
Powered by GoDaddy Website Builder